Impact Biomedical executes 1-for-12.62 reverse stock split

The company approved a 1-for-12.62 reverse stock split effective September 23, 2026, benefiting its proposed merger with Zoar Limited. This follows an approved discretionary split ratio and aims to satisfy NYSE American listing requirements.